Gibelin Cécilia, Avrillon Virginie, De La Fouchardiere Arnaud, Mc Leer-Florin Anne, Lantuejoul Sylvie, Fayette Jérôme
Resident of Pneumology, University of Lyon, France.
Clinical Oncology, Cancer Center « Centre Léon Bérard » Lyon, University of Lyon, France.
Lung Cancer. 2016 Dec;102:42-43. doi: 10.1016/j.lungcan.2016.10.005. Epub 2016 Oct 19.
Non-small cell lung cancers (NSCLCs) have molecular characterization and most druggable genetic and molecular abnormalities, such as EGFR, ERBB2 and BRAF mutations, and ALK and ROS1 rearrangements, have been observed in a subset of adenocarcinomas or large cell carcinomas [1]. Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3]. Here, we describe a patient with a SQCC harboring ROS1 rearrangement and a response to the target therapy, crizotinib.
